Healthcare
Vext Science, Inc.(VEXTF)
Live Price
Offline$0.19
-0.52% today
1Y Change
+100.00%
Window
Jun 20, 2025 โ Jun 8, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +45.2%
- EPS Growth
- +20.5%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 20, 2025 โ Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vext Science, Inc. (VEXTF) is a Healthcare stock with a market cap of $70.00M and listed on OTC. The stock last traded around $0.19 and up 100.0% across the available one-year price window (Jun 20, 2025 โ Jun 8, 2026). Baseline metrics include revenue growth of +45.2%, EPS growth of +20.5%, a dividend yield of 0.0%. What stands out right now is revenue +45.2%, EPS +20.5%, free cash flow +354.5% with operating margin -16.4% and ROIC -8.4%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VEXTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+45.2% vs +7.6% peer median
Operating Margin
Below sector median
-16.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +45.2% and EPS at +20.5%, with operating margin around -16.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +11.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +0.3% | +31.6% | +1.9% |
2026 Mar 31, 2026 | โ | +0.0% | +4.5% | +30.1% |
2025 Nov 20, 2025 | -51.6% | -1.5% | -0.8% | +28.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VEXTF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VEXTF Max Drawdown
-45.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VEXTF and SPY.
Company Overview
Vext Science, Inc.
Other OTC
Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. The company is involved in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. It also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen and Pure Touch Botanicals brands. In addition, the company offers Vapen clear infused products, THC chocolate bars, THC syrup, THC snacks, candies, and gummies under Vapen Kitchens brand. The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona .
- Leadership
- Eric J. Offenberger
- IPO Date
- May 28, 2019
- Employees
- 173
- Street Address
- 4152 North 39th Avenue
- Mailing
- Phoenix, AZ, 85019
- Region
- Phoenix, AZ, US
- Reporting Currency
- USD
- Investor Line
- +1 604 644 6403
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 12.1
- Price/Sales
- 1.3
- Price/Book
- 0.9
Growth
- Revenue
- +45.2%
- EPS
- +20.5%
- Free Cash Flow
- +354.5%
Profitability
- Gross Margin
- 25.4%
- Operating Margin
- -16.4%
- Net Margin
- -35.2%
- ROE
- -27.2%
- ROIC
- -8.4%
Balance Sheet
- Debt/Equity
- 0.63
- Current Ratio
- 0.59
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.